Breaking News Instant updates and real-time market news.

INSM

Insmed

$26.14

0.13 (0.50%)

08:12
02/15/19
02/15
08:12
02/15/19
08:12

Insmed upgraded to Outperform following Arikayce survey at JMP Securities

As previously reported, JMP Securities analyst Liisa Bayko upgraded Insmed to Outperform from Market Perform, stating that her survey of "early adopters" of Arikayce shows a high rate of utilization with a favorable early experience that is encouraging more usage. This suggests Arikayce will beat 2019 consensus, contends Bayko, who raised her 2019 Arikayce revenue estimates. She set a $40 price target on Insmed shares.

INSM Insmed
$26.14

0.13 (0.50%)

01/02/19
ADAM
01/02/19
INITIATION
Target $20
ADAM
Buy
Insmed initiated with a Buy at Canaccord
Canaccord analyst Dewey Steadman initiated Insmed with a Buy rating as he views the launch of Arikayce positively given the severe unmet need in nontuberculous mycobacterial lung disease and the potential for the drug to become core to the NTM treatment paradigm over time. He believes Insmend is well positioned as a specialty play and thinks the company has been unfairly caught up in broader infectious disease market meltdown as several antibiotic companies have disappointed investors. Steadman has a $20 price target on Insmed shares.
01/15/19
ADAM
01/15/19
NO CHANGE
Target $32
ADAM
Buy
Insmed price target raised to $32 from $20 at Canaccord
Canaccord analyst Dewy Steadman raised his price target on Insmed to $32 from $20 following its "blowout" preannouncement last week. The analyst is cautiously optimistic about 2019 performance as even a rock-bottom base revenue assumption is above consensus revenue. He also believes Arikayce will become core to the NTM treatment paradigm over time, making current valuation an attractive entry points for investors. Steadman reiterated his Buy rating on Insmed shares.
01/17/19
GSCO
01/17/19
UPGRADE
Target $35
GSCO
Buy
Insmed upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders upgraded Insmed to Buy and raised his price target for the shares to $35 from $29. The new target implies 52% upside from current share levels. The analyst says that following a "highly encouraging" first quarter of launch Arikayce, he sees a "beatable bar" in 2019. Strong early uptake bodes well for the long-term market opportunity in the U.S. and as Insmed seeks regulatory approval in Japan, Flanders tells investors in a research note. Physician diligence supports demand for Arikayce while the shares are inexpensive, adds the analyst. Further, he believes the company's label expansion studies could meaningfully expand the franchise opportunity if successful.
02/15/19
JMPS
02/15/19
UPGRADE
JMPS
Outperform
Insmed upgraded to Outperform from Market Perform at JMP Securities

TODAY'S FREE FLY STORIES

NVS

Novartis

$75.84

0.42 (0.56%)

05:38
04/24/19
04/24
05:38
04/24/19
05:38
Earnings
Novartis raises FY19 core operating income view to high single-digit growth »

Expects FY19 revenue to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 22

    May

  • 31

    May

NVS

Novartis

$75.84

0.42 (0.56%)

05:36
04/24/19
04/24
05:36
04/24/19
05:36
Earnings
Novartis reports Q1 core EPS $1.21, consensus $1.20 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 22

    May

  • 31

    May

VBIV

VBI Vaccines

$2.00

0.05 (2.56%)

05:34
04/24/19
04/24
05:34
04/24/19
05:34
Conference/Events
VBI Vaccines to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 23

    May

PLCE

Children's Place

$109.92

2.95 (2.76%)

05:34
04/24/19
04/24
05:34
04/24/19
05:34
Initiation
Children's Place initiated  »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAC

TransAlta

$6.88

-0.175 (-2.48%)

05:32
04/24/19
04/24
05:32
04/24/19
05:32
Hot Stocks
TransAlta comments on Mangrove Partners release, urges holders to vote BLUE card »

TransAlta commented on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

CRI

Carter's

$105.13

2.02 (1.96%)

05:31
04/24/19
04/24
05:31
04/24/19
05:31
Initiation
Carter's initiated  »

Carter's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 16

    May

STRL

Sterling Construction

$13.77

0.19 (1.40%)

05:30
04/24/19
04/24
05:30
04/24/19
05:30
Hot Stocks
Sterling Construction awarded $23M contract by UDOT »

Sterling Construction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

COST

Costco

$245.56

2.1 (0.86%)

05:27
04/24/19
04/24
05:27
04/24/19
05:27
Recommendations
Costco analyst commentary at Baird »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 30

    May

EBAY

eBay

$36.66

0.51 (1.41%)

05:22
04/24/19
04/24
05:22
04/24/19
05:22
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$262.32

1.39 (0.53%)

05:19
04/24/19
04/24
05:19
04/24/19
05:19
Recommendations
Abiomed analyst commentary at Piper Jaffray »

CMS proposed rate changes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 05

    Jun

  • 13

    Nov

MMSI

Merit Medical

$59.13

1.57 (2.73%)

05:16
04/24/19
04/24
05:16
04/24/19
05:16
Recommendations
Merit Medical analyst commentary at Piper Jaffray »

Piper calls Merit Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

  • 23

    May

HOLX

Hologic

$44.26

1.26 (2.93%)

05:13
04/24/19
04/24
05:13
04/24/19
05:13
Recommendations
Hologic analyst commentary at Piper Jaffray »

Hologic checks suggest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 07

    May

  • 29

    May

  • 05

    Jun

SYK

Stryker

$186.95

4.905 (2.69%)

05:09
04/24/19
04/24
05:09
04/24/19
05:09
Recommendations
Stryker analyst commentary at Piper Jaffray »

Stryker's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 08

    May

  • 29

    May

ICLK

iClick Interactive Asia

$3.89

-0.115 (-2.87%)

05:08
04/24/19
04/24
05:08
04/24/19
05:08
Hot Stocks
iClick enters marketing technology joint venture with VGI »

VGI Global Media and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$36.66

0.51 (1.41%)

05:05
04/24/19
04/24
05:05
04/24/19
05:05
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$38.92

-0.79 (-1.99%)

05:03
04/24/19
04/24
05:03
04/24/19
05:03
Downgrade
Harley-Davidson rating change  »

Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BBY

Best Buy

$73.60

1 (1.38%)

05:02
04/24/19
04/24
05:02
04/24/19
05:02
Upgrade
Best Buy rating change at Jefferies »

Best Buy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FOJCY

Fortum

$0.00

(0.00%)

05:00
04/24/19
04/24
05:00
04/24/19
05:00
Upgrade
Fortum rating change  »

Fortum upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$0.00

(0.00%)

04:58
04/24/19
04/24
04:58
04/24/19
04:58
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$11.99

0.46 (3.99%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Upgrade
Snap rating change at JPMorgan »

Snap upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIRS

Pieris Pharmaceuticals

$2.93

0.01 (0.34%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Conference/Events
Pieris Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 07

    May

MPSYF

Morphosys AG

$0.00

(0.00%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Conference/Events
Morphosys AG management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

MOR

MorphoSys

$24.78

0.7 (2.91%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Conference/Events
MorphoSys management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 08

    May

  • 20

    Jun

NTGN

Neon Therapeutics

$6.21

0.03 (0.49%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Conference/Events
Neon Therapeutics management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

AXU

Alexco Resource

$0.96

-0.0396 (-3.98%)

04:55
04/24/19
04/24
04:55
04/24/19
04:55
Conference/Events
Alexco Resource management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.